Nucana Plc (NCNA) - Form 20-F Summary
Business Context and Reporting Period
Company: Nucana Plc
Reporting Period: Fiscal year ended December 31, 2025
Filing Date: March 19, 2026
Business Overview: Nucana is a clinical-stage biopharmaceutical company developing "ProTide" technology to transform nucleoside analogs into more effective cancer treatments. The company has no approved products and generates no revenue from product sales. Its primary focus is on two lead candidates: NUC-7738 (Phase 1/2 in melanoma) and NUC-3373 (Phase 1b/2 in solid tumors and lung cancer). A third candidate, Acelarin, had its Phase 3 trial discontinued in 2022.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 (£) | 2024 (£) |
|---|---|---|
| Revenue | 0 | 0 |
| Net Loss | (29,353,000) | (18,997,000) |
| Operating Loss | (20,110,000) | (22,809,000) |
| Research & Development Expenses | (12,737,000) | (18,017,000) |
| Administrative Expenses | (8,096,000) | (4,988,000) |
| Finance Expense (Non-cash) | (12,648,000) | 0 |
| Cash and Cash Equivalents (End of Period) | 24,251,000 | 6,749,000 |
| Accumulated Deficit | (252,334,000) | (224,294,000) |
| Net Cash Used in Operating Activities | (7,467,000) | (19,118,000) |
Note: All figures in thousands of GBP unless otherwise noted. The 2025 Net Loss includes a significant non-cash finance expense of £12.6 million related to the fair value revaluation of derivative financial instruments (warrants).
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately £10.4 million (55%) compared to 2024. This was primarily driven by a £12.6 million non-cash revaluation loss on warrants issued in May 2025, partially offset by a decrease in operating expenses.
- R&D Expense Decrease: R&D expenses decreased by £5.3 million (29%) due to reduced clinical trial spending, specifically the discontinuation of the NuTide:323 trial, partially offset by increased spending on the NuTide:701 trial and higher share-based payment expenses.
- Administrative Expense Increase: Administrative expenses increased by £3.1 million (62%), driven by a £2.5 million increase in share-based payments and £1.4 million in professional fees related to warrant issuance.
- Liquidity Improvement: Cash and cash equivalents increased significantly from £6.7 million to £24.3 million, fueled by £25.0 million in net cash from financing activities (equity issuances and warrant exercises).
- Share Capital Restructuring: In April 2025, the company subdivided its share capital, creating deferred shares. In August 2025, the ADS ratio was changed from 1:25 to 1:5,000 to maintain Nasdaq listing compliance.
Guidance, Outlook, and Risks
Outlook and Guidance:
- Cash Runway: Management believes current cash resources (£24.3 million) are sufficient to fund anticipated operations into 2029.
- NUC-7738: The company expects to report final data from the Phase 2 expansion study (NuTide:701) in 2026 and seeks FDA regulatory guidance regarding the registrational pathway for melanoma in 2026.
- NUC-3373: The company is evaluating optimal combinations and indications for further clinical trials, with a development plan expected to be announced in 2026.
Key Risks and Contingencies:
- Going Concern: While the company has a 12-month going concern assessment, it has incurred recurring losses and an accumulated deficit of £252.3 million. Future profitability depends entirely on successful development, approval, and commercialization of product candidates.
- Capital Requirements: The company will require substantial additional funding to continue operations beyond the current runway. Failure to secure financing could force curtailment of development programs.
- Regulatory and Clinical Risk: There is no assurance that NUC-7738 or NUC-3373 will receive regulatory approval. Clinical trials may fail to meet endpoints, or safety issues may arise.
- Derivative Liabilities: The company issued warrants in May 2025 classified as derivative liabilities. While these were largely exercised or cancelled by year-end, the volatility in their fair value significantly impacted the 2025 net loss.
- Intellectual Property: The company relies on licenses from Cardiff University and Cardiff ProTides Ltd. Breach of these agreements could result in loss of rights to key intellectual property.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the £24.3 million cash balance against the projected burn rate into 2029, considering potential delays in clinical trials.
- Warrant Liability Resolution: Confirm that all derivative warrant liabilities have been fully settled or converted to equity as of the balance sheet date to prevent future non-cash losses.
- Clinical Trial Progress: Monitor the upcoming 2026 data readouts for NUC-7738 (NuTide:701) and the strategic decision-making for NUC-3373.
- Share Dilution: Review the impact of the recent share subdivisions and the large number of outstanding share options (over 3.4 billion options outstanding as of Dec 31, 2025) on future dilution.
- Regulatory Status: Track the FDA guidance meeting scheduled for 2026 regarding NUC-7738, as this is a critical milestone for the company's primary asset.